Price$154.85-0.44 (-0.28%)
01:30 PM07:45 PM
News · 26 weeks114+83%
2025-10-262026-04-19
Mix6090d
- Insider25(42%)
- Other18(30%)
- SEC Filings10(17%)
- Analyst3(5%)
- Earnings2(3%)
- Dividends1(2%)
- Other1(2%)
Latest news
25 items- PRBD Earns Industry Top Honors for Transparency, Resiliency and PartnershipFRANKLIN LAKES, N.J., April 16, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, has been recognized by the Healthcare Industry Resilience Collaborative (HIRC) as the only supplier to receive HIRC's inaugural Member Choice Awards across three categories, Transparency, Resiliency and Partnership. Selected by HIRC members based on real–world customer experience, the awards acknowledge suppliers whose actions strengthen supply chain transparency, resilience, and continuity of patient care. Transparency Award: recognize
- ANALYSTGoldman resumed coverage on Becton Dickinson with a new price targetGoldman resumed coverage of Becton Dickinson with a rating of Neutral and set a new price target of $167.00
- SECBecton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BECTON DICKINSON & CO (0000010795) (Filer)
- PRBD to Announce Financial Results for its Second Quarter of Fiscal 2026FRANKLIN LAKES, N.J., April 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, May 7, 2026 to discuss the Company's financial results for its second quarter of fiscal year 2026, which ended on March 31, 2026, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors, and a replay will be made available shortly after the call at the same website. Prior to the call, the Company will issue a news release and related presentation materials that will inclu
- PRRick Byrd to Retire from BDFRANKLIN LAKES, N.J., April 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Richard (Rick) Byrd has informed the company of his intent to retire after nearly 25 years with BD. Byrd is currently executive vice president and president of the Interventional Segment at BD, a position he has held since September 2022. During his tenure, Byrd held several leadership roles including worldwide president of Medication Delivery Solutions and worldwide president of Preanalytical Systems. Prior to joini
- PRFor Women Managing Nighttime Incontinence, Better Sleep and Comfort Start with BD® PureWick® Urine Collection SystemNew study findings published in the Journal of Clinical Medicine highlight the ease of use and comfort of BD PureWick® Female External Catheter can support a better night's restFRANKLIN LAKES, N.J. , April 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced new clinical findings revealing that women managing nighttime urinary incontinence reported better sleep and greater overall comfort when using the BD PureWick® Urine Collection System. According to the study, published in the Journal of Clinical Medicine, participants highlighted the system's ease of use and the non-invasive design of the PureWick® Flex Femal
- PRBD Delivers Next‑Generation TIPS Innovation to Advance Portal Hypertension Care Across the European UnionCE Marking and ARCH clinical trial data position the Liverty™ TIPS Stent Graft to expand treatment options for patients with advanced liver diseaseFRANKLIN LAKES, N.J., April 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced application of CE Mark for the Liverty™ TIPS Stent Graft, delivering innovation to portal hypertension care across the European Union. Designed to expand treatment options for patients with cirrhosis and complications of portal hypertension, our next‑generation, adjustable‑diameter device represents the latest advancement by BD in interventional therapies addressing complex liver disease. S
- PRWhen Every Beat Matters, BD Helps Clinicians Eliminate Blind Spots with Continuous, Noninvasive Blood Pressure InsightNew HemoSphere Stream™ Module expands access to continuous, noninvasive arterial waveform data across compatible bedside monitors and broader care settings, giving more clinicians real-time insight into more patients.FRANKLIN LAKES, N.J. , April 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the launch of the HemoSphere Stream™ Module, a new innovation which gives clinicians continuous, noninvasive visibility into patients' blood pressure. The module delivers real-time, beat-to-beat arterial waveform data from a noninvasive finger cuff directly to compatible multiparameter patient monitors, helping clinician
- INSIDERSEC Form 4 filed by Neal Shana Carol4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- SECBecton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BECTON DICKINSON & CO (0000010795) (Filer)
- PRBD Launches AI-Enabled Medication Dispensing System to the European MarketAdvanced automation and connected data capabilities strengthen medication inventory control and enhance safety across pharmacy settings.FRANKLIN LAKES, N.J., April 1, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the launch of the BD® Pyxis™ Pro Dispensing Solution and BD® Incada™ Connected Care Platform in Europe. This next-generation medication dispensing system combines advanced automation and AI‑driven insights to modernize medication management, reduce disruptions, and improve efficiency while helping clinicians spend more time on patient care.
- INSIDERSEC Form 4 filed by Feld Michael4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- INSIDEREVP and General Counsel Minnix Lanesha was granted 7,492 shares (SEC Form 4)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- INSIDERNew insider Minnix Lanesha claimed no ownership of stock in the company (SEC Form 3)3 - BECTON DICKINSON & CO (0000010795) (Issuer)
- INSIDERInterim CFO Roque Vitor was granted 931 shares, increasing direct ownership by 17% to 6,510 units (SEC Form 4)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- INSIDERSVP Controller & CAO Spikner Pamela L. was granted 931 shares, increasing direct ownership by 39% to 3,323 units (SEC Form 4)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- PRBD Pioneers New Standard in Surgical Safety with FDA-Cleared Surgiphor™ 1000mL for Wound IrrigationThe first and only innovation of its kind to receive 510(k) clearance, Surgiphor™ 1000mL empowers surgical teams with a consistent, antimicrobial solution designed to improve patient care and operating room (OR) efficiencyFRANKLIN LAKES, N.J., March 2, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Surgiphor™ 1000mL. As the first and only 1000 mL antimicrobial irrigation system specifically designed for powered lavage, Surgiphor™ 1000mL provides a standardized, OR-ready solution that enhances surgical safety and efficacy.
- INSIDEREVP, Chief Revenue Officer Feld Michael sold $13,638 worth of shares (75 units at $181.84), decreasing direct ownership by 0.35% to 21,308 units (SEC Form 4)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- SECBecton Dickinson and Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BECTON DICKINSON & CO (0000010795) (Filer)
- PRBecton, Dickinson and Company Announces Pricing of the Tender Offers and Amounts Accepted for PurchaseFRANKLIN LAKES, N.J., Feb. 25, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) (the "Company" or "BD"), a leading global medical technology company, today announced the consideration payable in connection with its previously announced Tender Offers (as defined below) to purchase for cash up to $2,000,000,000 aggregate purchase price, excluding the applicable Accrued Interest (as defined below) (which, subject to applicable law, may be increased or decreased in the Company's sole discretion, the "Aggregate Offer Cap") of its (i) 6.700% Senior Notes due 2026, (ii) 7.000% Senior Debentures due 2027, (iii) 6.700% Senior Debentures due 2028, (iv) 6.000% Senior Notes due 2039, (
- PRBecton, Dickinson and Company Announces Early Tender Results and Upsizing of Offer SubCap and Aggregate Offer CapFRANKLIN LAKES, N.J., Feb. 25, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) (the "Company" or "BD"), a leading global medical technology company, today announced the early tender results for its previously announced Tender Offers (as defined below) to purchase for cash certain of its outstanding debt securities listed in the table below. In making the announcement, the Company has exercised its previously disclosed right to amend such Tender Offers to (i) increase the Offer SubCap (as defined below) with respect to the 4.685% Senior Notes due 2044 (the "4.685% Senior Notes") and (ii) increase the Aggregate Offer Cap (as defined below) from $1,600,000,000 to an aggregate
- PRBD to Present at Barclays 28th Annual Global Healthcare ConferenceFRANKLIN LAKES, N.J., Feb. 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 8:30 am Eastern Time. The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion.About BDBD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems a
- PRBD Expands Testing Capabilities to Help Clinicians Improve Diagnostic Accuracy and EfficiencyThe BD Vacutainer® Urine Complete Cup Kit preserves specimen quality, streamlines testing, and helps reduce repeat collections to support better patient careFRANKLIN LAKES, N.J., Feb. 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the launch of the BD Vacutainer® Urine Complete Cup Kit, a three-tube collection system that expands and supports broader testing capabilities from a single urine specimen. The new kit is designed to preserve sample integrity and improve workflow efficiency, while red
- PRLanesha Minnix Named General Counsel for BDFRANKLIN LAKES, N.J., Feb. 19, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Lanesha Minnix has been named executive vice president and general counsel for the company, effective March 16. Minnix will be responsible for leading the Law Group and Public Affairs at BD. She will report to Tom Polen, chairman, CEO and president of BD, and serve on the BD Executive Leadership Team.Minnix most recently served as executive vice president and chief legal officer of Walgreens Boots Alliance, where she
- INSIDERDirector Scott Bertram L sold $174,027 worth of shares (953 units at $182.61), decreasing direct ownership by 3% to 36,763 units (SEC Form 4)4 - BECTON DICKINSON & CO (0000010795) (Issuer)